Frequent Mutation of Isocitrate Dehydrogenase<i>(IDH)1</i>and<i>IDH2</i>in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger(Massachusetts Eye and Ear Infirmary), A. John Iafrate(Massachusetts General Hospital), Hannah M. Liebman(Massachusetts General Hospital), David P. Schenkein(Agios Pharmaceuticals (United States)), Vikram Deshpande(Beth Israel Deaconess Medical Center), Kenneth K. Tanabe(Harvard University), Marek Ancukiewicz(Bridge University), Kimberly Straley(Agios Pharmaceuticals (United States)), Leif W. Ellisen(Harvard University), Dora Dias‐Santagata(Harvard University), Valeria R. Fantin(AVEO Oncology (United States)), Hector U. Lopez(Harvard University), David P. Ryan(East Carolina University), Kenneth C. Fan(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Eunice L. Kwak(Harvard University), Aram F. Hezel(University of Rochester Medical Center)
Cited by 724
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k